Tokushima University / Educator and Researcher Directory --- Tonoiso, Chisato

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Akinari Kasai, Jinsei Miyoshi, Yasushi Sato, Koichi Okamoto, Hiroshi Miyamoto, Takashi Kawanaka, Chisato Tonoiso, Masafumi Harada, Masakazu Goto, Takahiro Yoshida, Akihiro Haga and Tetsuji Takayama : A novel CT-based radiomics model for predicting response and prognosis of chemoradiotherapy in esophageal squamous cell carcinoma., Scientific Reports, Vol.14, No.1, 2039, 2024. (Summary) No clinically relevant biomarker has been identified for predicting the response of esophageal squamous cell carcinoma (ESCC) to chemoradiotherapy (CRT). Herein, we established a CT-based radiomics model with artificial intelligence (AI) to predict the response and prognosis of CRT in ESCC. A total of 44 ESCC patients (stage I-IV) were enrolled in this study; training (n = 27) and validation (n = 17) cohorts. First, we extracted a total of 476 radiomics features from three-dimensional CT images of cancer lesions in training cohort, selected 110 features associated with the CRT response by ROC analysis (AUC ≥ 0.7) and identified 12 independent features, excluding correlated features by Pearson's correlation analysis (r ≥ 0.7). Based on the 12 features, we constructed 5 prediction models of different machine learning algorithms (Random Forest (RF), Ridge Regression, Naive Bayes, Support Vector Machine, and Artificial Neural Network models). Among those, the RF model showed the highest AUC in the training cohort (0.99 [95%CI 0.86-1.00]) as well as in the validation cohort (0.92 [95%CI 0.71-0.99]) to predict the CRT response. Additionally, Kaplan-Meyer analysis of the validation cohort and all the patient data showed significantly longer progression-free and overall survival in the high-prediction score group compared with the low-prediction score group in the RF model. Univariate and multivariate analyses revealed that the radiomics prediction score and lymph node metastasis were independent prognostic biomarkers for CRT of ESCC. In conclusion, we have developed a CT-based radiomics model using AI, which may have the potential to predict the CRT response as well as the prognosis for ESCC patients with non-invasiveness and cost-effectiveness. (Keyword) Humans / Esophageal Squamous Cell Carcinoma / Artificial Intelligence / Bayes Theorem / Esophageal Neoplasms / Radiomics / Prognosis / Chemoradiotherapy / Tomography, X-Ray Computed (Tokushima University Institutional Repository) ● Metadata: 119113 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-024-52418-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38263395 ● Search Scopus @ Elsevier (PMID): 38263395 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-024-52418-4 (Tokushima University Institutional Repository: 119113, DOI: 10.1038/s41598-024-52418-4, PubMed: 38263395)
2.	Daisuke Satoh, Motoharu Sasaki, Yuji Nakaguchi, Takeshi Kamomae, Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Yuki Kanazawa, Masataka Oita, Akimi Kajino, Akira Tsuzuki and Hitoshi Ikushima : Differences between professionals in planning treatment for patients with stage III lung cancer using treatment-planning QA software, Reports of Practical Oncology and Radiotherapy, Vol.28, No.5, 671-680, 2023. (Summary) The quality of treatment planning for stage III non-small cell lung cancer varies within and between facilities due to the different professions involved in planning. Dose estimation parameters were calculated using a feasibility dose-volume histogram (FDVH) implemented in the treatment planning quality assurance software PlanIQ. This study aimed to evaluate differences in treatment planning between occupations using manual FDVH-referenced treatment planning to identify their characteristics. The study included ten patients with stage III non-small cell lung cancer, and volumetric-modulated arc therapy was used as the treatment planning technique. Fifteen planners, comprising five radiation oncologists, five medical physicists, and five radiological technologists, developed treatment strategies after referring to the FDVH. Medical physicists had a higher mean dose at D98% of the planning target volume (PTV) and a lower mean dose at D2% of the PTV than those in other occupations. Medical physicists had the lowest irradiation lung volumes (V5 Gy and V13 Gy) compared to other professions, and radiation oncologists had the lowest V20 Gy and mean lung dose. Radiological technologists had the highest irradiation volumes for dose constraints at all indexes on the normal lung volume. The quality of the treatment plans developed in this study differed between occupations due to their background expertise, even when an FDVH was used as a reference. Therefore, discussing and sharing knowledge and treatment planning techniques among professionals is essential to determine the optimal treatment plan for each facility and patient. (Keyword) Non-small-cell lung cancer / PlanIQ / Treatment planning quality / Volumetric-modulated arc therapy (Link to Publication Site) ● Publication site (DOI): 10.5603/rpor.97511 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38179286 ● Search Scopus @ Elsevier (PMID): 38179286 ● Search Scopus @ Elsevier (DOI): 10.5603/rpor.97511 (DOI: 10.5603/rpor.97511, PubMed: 38179286)
3.	Yoshito Kusuhara, Tomoya Fukawa, Tomoharu Fukumori, Yoshiteru Ueno, Kei Daizumoto, Yutaro Sasaki, Ryotaro Tomida, Yasuyo Yamamoto, Kunihisa Yamaguchi, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima, Hiro-omi Kanayama and Masayuki Takahashi : Effect of Positive Biopsy Core Rate on Low-dose-rate Brachytherapy Outcomes in Intermediate-risk Prostate Cancer., Anticancer Research, Vol.43, No.10, 4627-4635, 2023. (Summary) Positive core ratios observed on prostate biopsy correlated with higher recurrence rates after LDR-BT. This indicates that the proportion of positive cores in the biopsy may be an important factor in predicting the likelihood of recurrence, especially for patients with GG3 PCa. (Keyword) Male / Humans / Retrospective Studies / Brachytherapy / Prostatic Neoplasms / Neoplasm Grading / Biopsy / Prostate-Specific Antigen (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.16657 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37772553 ● Search Scopus @ Elsevier (PMID): 37772553 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.16657 (DOI: 10.21873/anticanres.16657, PubMed: 37772553)
4.	Yoshiteru Ueno, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Ryotaro Tomida, Yasuyo Yamamoto, Kunihisa Yamaguchi, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima, Masayuki Takahashi and Hiro-omi Kanayama : Prostate-specific Antigen Levels Following Brachytherapy Impact Late Biochemical Recurrence in Japanese Patients With Localized Prostate Cancer., In Vivo, Vol.37, No.2, 738-746, 2023. (Summary) PSA levels at 5 years post-treatment were associated with long-term recurrence of localized prostate cancer, which can help alleviate patient anxiety concerning prostate cancer recurrence if PSA levels remain low at 5 years after LDR-BT. (Keyword) Male / Humans / Prostate-Specific Antigen / Brachytherapy / Cohort Studies / East Asian People / Prostatic Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.13136 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36881090 ● Search Scopus @ Elsevier (PMID): 36881090 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.13136 (DOI: 10.21873/invivo.13136, PubMed: 36881090)
5.	Akiko Abe, Masao Yuasa, Yoshie Imai, Tomohiro Kagawa, Ayuka Mineda, Masato Nishimura, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima and Takeshi Iwasa : Extreme leanness, lower skeletal muscle quality, and loss of muscle mass during treatment are predictors of poor prognosis in cervical cancer treated with concurrent chemoradiation therapy, International Journal of Clinical Oncology, Vol.27, No.5, 983-991, 2022. (Summary) Human papillomavirus vaccination is not widespread in Japan, and the low screening rates result in many cases of locally advanced cervical cancer. We investigated the prognostic significance of sarcopenia in patients with cervical cancer to guide healthcare policies to improve treatment outcomes. This retrospective study included 83 patients with cervical cancer without distant metastasis who underwent primary concurrent chemoradiotherapy between 2013 and 2018. We analyzed the indicators of physical condition and muscle quantity using the SYNAPSE VINCENT software. Muscle mass and the relationship between treatment toxicity and prognosis were evaluated. The patients' median age was 60 (range 33-80) years. Cancer stage distribution was as follows: cT2b or higher, 84.3%; N1, 65.1%; and MA, 27.7%. The overall sarcopenia (skeletal muscle index [SMI] < 38.5) rate was 30.1%, and the rate was 33.9 and 22.2% in patients aged < 64 and ≥ 65 years, respectively. No correlation was observed between clinical stage and musculoskeletal indices. Treatment resulted in decreased body weight and SMI; after treatment, the sarcopenia rate increased to 37.3%. A higher intramuscular adipose tissue content (IMAC) reduced the number of chemotherapy cycles needed. Treatment-associated SMI decreases of ≥ 7% indicated poor prognosis, with significant differences in progression-free survival and overall survival (p = 0.013 and p = 0.012, respectively). Patients who were very lean (body mass index < 18.5 kg/m) before treatment had a poor prognosis (p = 0.016 and p < 0.001). Our findings emphasize the importance of assessing original nutritional status and maintaining muscle mass and quality during the treatment of patients with cervical cancer. (Keyword) Adult / Aged / Aged, 80 and over / Chemoradiotherapy / Female / Humans / Middle Aged / Muscle, Skeletal / Papillomavirus Infections / Papillomavirus Vaccines / Prognosis / Retrospective Studies / Sarcopenia / Thinness / Uterine Cervical Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-022-02140-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35212828 ● Summary page in Scopus @ Elsevier: 2-s2.0-85125283470 (DOI: 10.1007/s10147-022-02140-w, PubMed: 35212828, Elsevier: Scopus)
6.	Kenta Kitagawa, Hitoshi Ikushima, Motoharu Sasaki, Shunsuke Furutani, Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Takaharu Kudoh, Yohsuke Kanoh and Tsuzuki Akira : Effect of dental metal artifact conversion volume on dose distribution in head-and-neck volumetric-modulated arc therapy, Journal of Applied Clinical Medical Physics, Vol.21, No.12, 253-262, 2020. (Summary) Purpose: During treatment planning for head-and-neck volumetric-modulated arc therapy (VMAT), manual contouring of the metal artifact area of artificial teeth is done, and the area is replaced with water computed tomography (CT) values for dose calculation. This contouring of the metal artifact areas, which is performed manually, is subject to human variability. The purpose of this study is to evaluate and analyze the effect of inter-observer variation on dose distribution.Methods: The subjects were 25 cases of cancer of the oropharynx for which VMAT was performed. Six radiation oncologists (ROs) performed metal artifact contouring for all of the cases. Gross tumor volume, clinical target volume, planning target volume (PTV), and oral cavity were evaluated. The contouring of the six ROs was divided into two groups, small and large groups. A reference RO was determined for each group and the dose distribution was compared with those of the other radiation oncologists by gamma analysis (GA).As an additional experiment, we changed the contouring of each dental metal artifact area, creating enlarged contours (L), reduced contours (S), and undrawn contours (N) based on the contouring by the six ROs and compared these structure-sets.Results: The evaluation of inter-observer variation showed no significant difference between the large and small groups, and the GA pass rate was 100%. Similar results were obtained comparing structure-sets L and S, but in the comparison of structure-sets L and N, there were cases with pass rates below 70%.Conclusions: The results show that the artificial variability of manual artificial tooth metal artifact contouring has little effect on the dose distribution of VMAT. However, it should be noted that the dose distribution may change depending on the contouring method in cases where the overlap between PTV and metal artifact areas is large. (Keyword) dental metal artifact / head-and-neck / volumetric-modulated arc therapy (Tokushima University Institutional Repository) ● Metadata: 115924 (Link to Publication Site) ● Publication site (DOI): 10.1002/acm2.13101 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33226172 ● Summary page in Scopus @ Elsevier: 2-s2.0-85097008301 (Tokushima University Institutional Repository: 115924, DOI: 10.1002/acm2.13101, PubMed: 33226172, Elsevier: Scopus)
7.	Shunsuke Furutani, Hitoshi Ikushima, Motoharu Sasaki, Chisato Tonoiso, Ayaka Takahashi, Akiko Kubo, Takashi Kawanaka and Masafumi Harada : Clinical outcomes of hypofractionated image-guided multifocal irradiation using volumetric-modulated arc therapy for brain metastases., Journal of Radiation Research, Vol.60, No.1, 134-141, 2019. (Summary) Volumetric-modulated arc therapy (VMAT) can be used to design hypofractionated radiotherapy treatment plans for multiple brain metastases. The purpose of this study was to evaluate treatment outcomes of hypofractionated image-guided multifocal irradiation using VMAT (HFIGMI-VMAT) for brain metastases. From July 2012 to December 2016, 67 consecutive patients with 601 brain metastases were treated with HFIGMI-VMAT at our institution. The prescribed dose was 50 Gy to a 95% volume of the planning target volume in 10 fractions. Fifty-five of the 67 patients had non-small-cell lung cancer, and the remaining 12 had other types of cancer. The median number of brain metastases was five, and the median maximum diameter was 1.2 cm. The median duration of follow-up was 12.0 months (range, 1.9-44.8 months), and the median survival time 18.7 months. Four patients with six lesions had local recurrences. The local control rate in the 64 assessed patients was 98.4% and 95.3% at 6 and 12 months, respectively (three died before assessment). The local control rate for the 572 assessed lesions was 99.8% and 99.3% at 6 and 12 months, respectively. Thirty-nine patients developed distant brain metastases, the distant brain control rate being 59.7% and 40.5% at 6 and 12 months, respectively. Acute toxicities were generally mild (Grade 1-2). Three patients (4.5%) developed radiation necrosis requiring corticosteroid therapy. The HFIGMI-VMAT technique with flat dose delivery was well tolerated and achieved excellent local control. This technique is a promising treatment option for patients with multiple and large brain metastases. (Tokushima University Institutional Repository) ● Metadata: 115535 (Link to Publication Site) ● Publication site (DOI): 10.1093/jrr/rry091 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30445426 ● Search Scopus @ Elsevier (PMID): 30445426 ● Search Scopus @ Elsevier (DOI): 10.1093/jrr/rry091 (Tokushima University Institutional Repository: 115535, DOI: 10.1093/jrr/rry091, PubMed: 30445426)

Proceeding of International Conference:

1.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Hitoshi Ikushima, Masafumi Harada and Kawanaka Taeko : Initial Experience and Evaluation of Safety in Hypofractionated Accelerated Partial Breast irradiation using a Brachytherapy Multi-catheter Approach, FARO & KOSRO 2023, Seul, Korea, Oct. 2023.
2.	Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo and Hitoshi Ikushima : Compatibility of SAVI applicator and resection cavity underwent cylindrical breast resection for early-stage breast cancer and its solution: initial experience of Hybrid APBI, RSNA2021, Chicago, Nov. 2020.
3.	Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Chisato Tonoiso, Hitoshi Ikushima and Masafumi Harada : Long-Term Outcome of Low-Dose Rate Brachytherapy with I-125 Seeds as a Monotherapy for High-Risk Prostate Cancer Patients: A Propensity Score-Matched Analysis, RSNA2018, Nov. 2018.

Proceeding of Domestic Conference:

1.	Takashi Kawanaka, Hitoshi Ikushima, Masato Nishimura, Akiko Abe, Akiko Kubo and Chisato Tonoiso : 18=F Fluorodeoxyglucose Positron Emission Tomographyによる子宮頸癌放射線治療後の予後予測, 第66回日本婦人科腫瘍学会学術講演会, Jul. 2024.
2.	Chisato Tonoiso, Hitoshi Ikushima, Akihiro Haga, Motoharu Sasaki, Takashi Kawanaka, Akiko Kubo, Masato Nishimura and Akiko Abe : 子宮頸癌リンパ節転移の術前予測におけるMRIレディオミクス解析の有用性, 第66回日本婦人科腫瘍学会学術講演会, Jul. 2024.
3.	Takaharu Kudoh, Keiko Kudoh, Natsumi Takamaru, Akira Takahashi, Naito Kurio, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Youji Miyamoto and Hitoshi Ikushima : Unilateral Neck Volumetric-Modulated Arc Therapy, 日本歯科放射線学会第64回学術大会, May 2024.
4.	Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : 小線源治療によるAPBIを地域連携で行うBra-Shiの取り組み, 日本放射線腫瘍学会小線源治療部会第26回学術大会, May 2024.
5.	Akiko Kubo, Chisato Tonoiso, Takashi Kawanaka, 上野恵輝, Yoshito Kusuhara and Hitoshi Ikushima : 当院における高リスク前立腺癌患者に対する外照射併用小線源治療, 日本放射線腫瘍学会小線源治療部会第26回学術大会, May 2024.
6.	Akiko Kubo, Chisato Tonoiso, Takashi Kawanaka, Shunsuke Furutani, Yoshiteru Ueno, Yoshito Kusuhara, Tomoharu Fukumori, Hitoshi Ikushima and Masafumi Harada : 高リスク前立腺癌外照射併用小線源治療の後方視的検討, 日本放射線腫瘍学会第36回学術大会, Dec. 2023.
7.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Masafumi Harada and Hitoshi Ikushima : 小線源治療を用いたMulticatheter法によるHypofractionated APBIの初期導入経験, 日本放射線腫瘍学会第36回学術大会, Dec. 2023.
8.	Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima and Masafumi Harada : 中枢神経に再発を来した眼内悪性リンパ腫の2例, 日本放射線腫瘍学会第36回学術大会, Dec. 2023.
9.	竹内秀真, Motoharu Sasaki, 山下恭, Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, 下窪康史, 櫻川加奈子 and Hitoshi Ikushima : Deformable image registrationを用いた子宮頸がん放射線治療の合算線量評価, 日本放射線腫瘍学会小線源治療部会第25回学術大会, May 2023.
10.	Yuka Hiroshima, Takayoshi Shinya, Hitoshi Ikushima, Youichi Otomi, Hideki Otsuka, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Yasushi Takagi and Masafumi Harada : Multi-modality Imaging for the Patients with Metastatic Brain Tumors After Stereotactic Irradiation, The 82nd Annual Meeting of the Japan Radiological Society, Apr. 2023.
11.	Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : 再度の乳房加速部分照射を行った温存乳房内再発の1例, 日本放射線腫瘍学会第35回学術大会, Nov. 2022.
12.	Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo, Hitoshi Ikushima and Masafumi Harada : APBI臨床における最新の知見(SAVIハイブリッド照射ほか), 第11回WASAVlsの会, Jul. 2022.
13.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Hitoshi Ikushima and Masafumi Harada : SAVIアプリケーターと乳房部分切除後の切離腔の検討とその改善方法, 第30回日本乳癌学会学術総会, Jun. 2022.
14.	Akiko Kubo, Hitoshi Ikushima, Takashi Kawanaka, Chisato Tonoiso and Masafumi Harada : 子宮頸癌放射線治療における標的体積内同時ブースト(SIB)併用についての試み, 第136回日本医学放射線学会中国・四国地方会, Jun. 2022.
15.	Akiko Kubo, Hitoshi Ikushima, Chisato Tonoiso and Takashi Kawanaka : 当院でのVenezia applicatorによる子宮頸がん小線源治療の使用経験, 日本放射線腫瘍学会小線源治療部会第24回学術大会, May 2022.
16.	Akiko Kubo, Hitoshi Ikushima, 川中崇 and Chisato Tonoiso : 当院でのVenezia applicatorによる子宮頸がん小線源治療の使用経験, 小線源治療部会第24回学術大会, May 2022.
17.	Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima and 原田雅史 : 乳房の照射後に発生した放射線誘発腫瘍の一例, 日本放射線腫瘍学会第34回学術大会, Nov. 2021.
18.	Akiko Kubo, Hitoshi Ikushima, Takashi Kawanaka, Chisato Tonoiso, Takaharu Kudoh and 原田雅史 : 子宮頸癌化学放射線治療後の照射野内リンパ節転移についての検討, 日本放射線腫瘍学会第34回学術大会, Nov. 2021.
19.	Takaharu Kudoh, Akihiro Haga, Motoharu Sasaki, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani and Hitoshi Ikushima : Radiomicsの手法を用いたPETによる舌癌頸部リンパ節転移の予測, 日本放射線腫瘍学会第33回学術大会, Oct. 2020.
20.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso and Hitoshi Ikushima : Single-entry applicatorとinterstitial needleを併用した小線源治療によるAPBIの1例, 日本放射線腫瘍学会第33回学術大会, Oct. 2020.
21.	Akiko Kubo, Hitoshi Ikushima, Chisato Tonoiso, Takashi Kawanaka, Shunsuke Furutani and Masafumi Harada : 腋か領域を含めた乳癌術後照射における放射線肺臓炎の検討, 日本放射線腫瘍学会第32回学術大会, Nov. 2019.
22.	Chisato Tonoiso, Akihiro Haga, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh, Hitoshi Ikushima and Masafumi Harada : 子宮頸部扁平上皮癌における予後因子の検討, 日本放射線腫瘍学会第32回学術大会, Nov. 2019.
23.	Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 当院におけるSAVIアプリケータを用いたAPBIの術式と整合性についての検討, 日本放射線腫瘍学会第32回学術大会, Nov. 2019.
24.	Shunsuke Furutani, Hitoshi Ikushima, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka and Masafumi Harada : 非小細胞肺癌能転移に対する全脳照射の局所制御に関する検討, 日本放射線腫瘍学会第32回学術大会, Nov. 2019.
25.	Chisato Tonoiso, 高橋彩加, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Takaharu Kudoh, Hitoshi Ikushima and Masafumi Harada : 乳房原発悪性リンパ腫の1 例, 第54回日本医学放射線学会秋季臨床大会, Oct. 2018.
26.	Akiko Kubo, 高橋彩加, Chisato Tonoiso, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 子宮頚部扁平上皮癌放射線治療後局所残存を疑った症例, Oct. 2018.
27.	高橋彩加, Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 乳癌放射線治療後の難治性潰瘍に対して胸壁再建を施行した1 例, 第54回日本医学放射線学会秋季臨床大会, Oct. 2018.
28.	Akiko Kubo, Hitoshi Ikushima, Chisato Tonoiso, Takashi Kawanaka and Shunsuke Furutani : Image registration softwareを用いた子宮頸癌放射線治療の統合線量評価の検討, Jun. 2018.
29.	高橋彩加, Shunsuke Furutani, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Hitoshi Ikushima, Masafumi Harada, Akiko Abe and Masato Nishimura : 子宮頸部及び膣の異形成・上皮内癌に対する高線量率小線源治療, Jun. 2018.
30.	三橋遼太, Takashi Kawanaka, Akiko Kubo, Chisato Tonoiso, 高橋彩加, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 子宮頚部小細胞癌に対して放射線治療を行った2症例, Jun. 2018.
31.	Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Masafumi Harada : 放射線治療を施行した乳房原発悪性リンパ腫の1例, May 2018.

Assistant Professor : Tonoiso, Chisato

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Proceeding of International Conference:

Proceeding of Domestic Conference: